CD274 and neoplasm: Only a subset of TNBC patients with a pre-existing “hot” (inflamed) tumor immune microenvironment (TIME) that contains high PD-L1 expression or enriched tumor-infiltrating lymphocytes (TILs) may benefit from the combined treatment of chemotherapy and pembrolizumab11,12.